You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 131 No. 7, July 1995 TABLE OF CONTENTS
  Archives
  •  Online Features
  Correspondence: Vignettes
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citing articles on Web of Science (2)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Cutaneous Chronic Graft-vs-Host Disease and Hepatitis C Virus

Anne Bouloc, MD; Jean-Michel Pawlotsky, MD; Valérie Choukroun, MD; Françoise Norol, MD; Jean-Paul Vernant, MD; Jean Revuz, MD
Créteil

Martine Bagot, MD, PhD
Department of Dermatology Henri Mondor Hospital 5 Ave du Maréchal de Lattre de Tassigny 94010 Cretéil, France

Arch Dermatol. 1995;131(7):853-855.

Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Chronic graft-vs-host disease (GVHD) is a significant problem in patients who undergo bone marrow transplantation (BMT). It shares common clinical and histologic characteristics with lichen planus. The association of hepatitis C virus (HCV)-induced chronic hepatitis and lichen planus has been reported recently.1 To evaluate the possible role of HCV in the pathogenesis of chronic GVHD, two studies were performed in the BMT unit of our institution.

Patients and Methods.Cohort Study.

One hundred twenty-six consecutive patients who underwent allogeneic BMT between January 1987 and December 1991, with more than 6 months of follow-up post-BMT, were analyzed retrospectively. The mean age was 31 years. Chronic GVHD was defined as previously.2 Serum samples were obtained before and after BMT (mean delay, 11 months; [range, 6 to 54 months]). Anti-HCV antibodies were sought by a second-generation enzyme-linked immunosorbent assay (ELISA 2.0, Ortho Diagnostic Systems, Raritan, NJ) and a second-generation recombinant immunoblot . . . [Full Text PDF of this Article]



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1995 American Medical Association. All Rights Reserved.